Development and evaluation of á-arbutin loaded nanostructured lipid carriers for enhanced in-vitro cytotoxic activity in melanoma

Mahmut Ozan Toksoy; İlhan Sabancılar

Makale detayları

Development and evaluation of á-arbutin loaded nanostructured lipid carriers for enhanced in-vitro cytotoxic activity in melanoma

Yazarlar:

Mahmut Ozan Toksoy | İlhan Sabancılar

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmacology and Pharmaceutical Sciences (Other)

Dergi:

Journal of Research in Pharmacy Vol.29 Issue 4, pp.1712-1725

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001342460

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 The aim of this study was to develop and optimize α-arbutin-loaded nanostructured lipid carriers Ar- NLCs using the QbD. Additionally, the formulation studies, in-vitro and ex-vivo performance of Ar-NLCs were assessed, along with their cytotoxic efficacy in melanoma cells. The Ar-NLCs were fabricated using the high-speed homogenization-ultrasonication method, incorporating Gelucire 4816, Castor oil, Capryol 90, and Tween 80. To analyze the impact of factors on Ar-NLCs, the Box-Behnken design BBD was utilized. The Ar-NLCs were characterized by particle size, polydispersity index, morphology, zeta potential, release kinetics, permeation, flux and stability. Additionally, Ar-NLCs cytotoxicity was assessed using the A375 cells. The Ar-NLCs demonstrated a particle size of 228.7  44.5 nm, a zeta potential of -14.2  2.64 mV respectively. The entrapment efficiency was 67.62  4.46. The α- arbutin release from NLCs followed Weibull kinetics. Notably, Ar-NLCs demonstrated a 2.53-fold higher permeability compared to Ar-SOL. Furthermore, Ar-NLCs exhibited significantly stronger cytotoxic effects against melanoma cells than Ar-SOL. This study reports the successful development of Ar-NLCs using a QbD approach. Enhanced transdermal permeability, enhanced cytotoxicity on melanoma cells, and sustained release of α-arbutin from NLCs were achieved. These findings indicate that NLCs offer a viable alternative drug delivery system for transdermal applications.

 The aim of this study was to develop and optimize α-arbutin-loaded nanostructured lipid carriers Ar- NLCs using the QbD. Additionally, the formulation studies, in-vitro and ex-vivo performance of Ar-NLCs were assessed, along with their cytotoxic efficacy in melanoma cells. The Ar-NLCs were fabricated using the high-speed homogenization-ultrasonication method, incorporating Gelucire 4816, Castor oil, Capryol 90, and Tween 80. To analyze the impact of factors on Ar-NLCs, the Box-Behnken design BBD was utilized. The Ar-NLCs were characterized by particle size, polydispersity index, morphology, zeta potential, release kinetics, permeation, flux and stability. Additionally, Ar-NLCs cytotoxicity was assessed using the A375 cells. The Ar-NLCs demonstrated a particle size of 228.7  44.5 nm, a zeta potential of -14.2  2.64 mV respectively. The entrapment efficiency was 67.62  4.46. The α- arbutin release from NLCs followed Weibull kinetics. Notably, Ar-NLCs demonstrated a 2.53-fold higher permeability compared to Ar-SOL. Furthermore, Ar-NLCs exhibited significantly stronger cytotoxic effects against melanoma cells than Ar-SOL. This study reports the successful development of Ar-NLCs using a QbD approach. Enhanced transdermal permeability, enhanced cytotoxicity on melanoma cells, and sustained release of α-arbutin from NLCs were achieved. These findings indicate that NLCs offer a viable alternative drug delivery system for transdermal applications.

 The aim of this study was to develop and optimize α-arbutin-loaded nanostructured lipid carriers Ar- NLCs using the QbD. Additionally, the formulation studies, in-vitro and ex-vivo performance of Ar-NLCs were assessed, along with their cytotoxic efficacy in melanoma cells. The Ar-NLCs were fabricated using the high-speed homogenization-ultrasonication method, incorporating Gelucire 4816, Castor oil, Capryol 90, and Tween 80. To analyze the impact of factors on Ar-NLCs, the Box-Behnken design BBD was utilized. The Ar-NLCs were characterized by particle size, polydispersity index, morphology, zeta potential, release kinetics, permeation, flux and stability. Additionally, Ar-NLCs cytotoxicity was assessed using the A375 cells. The Ar-NLCs demonstrated a particle size of 228.7  44.5 nm, a zeta potential of -14.2  2.64 mV respectively. The entrapment efficiency was 67.62  4.46. The α- arbutin release from NLCs followed Weibull kinetics. Notably, Ar-NLCs demonstrated a 2.53-fold higher permeability compared to Ar-SOL. Furthermore, Ar-NLCs exhibited significantly stronger cytotoxic effects against melanoma cells than Ar-SOL. This study reports the successful development of Ar-NLCs using a QbD approach. Enhanced transdermal permeability, enhanced cytotoxicity on melanoma cells, and sustained release of α-arbutin from NLCs were achieved. These findings indicate that NLCs offer a viable alternative drug delivery system for transdermal applications.

 The aim of this study was to develop and optimize α-arbutin-loaded nanostructured lipid carriers Ar- NLCs using the QbD. Additionally, the formulation studies, in-vitro and ex-vivo performance of Ar-NLCs were assessed, along with their cytotoxic efficacy in melanoma cells. The Ar-NLCs were fabricated using the high-speed homogenization-ultrasonication method, incorporating Gelucire 4816, Castor oil, Capryol 90, and Tween 80. To analyze the impact of factors on Ar-NLCs, the Box-Behnken design BBD was utilized. The Ar-NLCs were characterized by particle size, polydispersity index, morphology, zeta potential, release kinetics, permeation, flux and stability. Additionally, Ar-NLCs cytotoxicity was assessed using the A375 cells. The Ar-NLCs demonstrated a particle size of 228.7  44.5 nm, a zeta potential of -14.2  2.64 mV respectively. The entrapment efficiency was 67.62  4.46. The α- arbutin release from NLCs followed Weibull kinetics. Notably, Ar-NLCs demonstrated a 2.53-fold higher permeability compared to Ar-SOL. Furthermore, Ar-NLCs exhibited significantly stronger cytotoxic effects against melanoma cells than Ar-SOL. This study reports the successful development of Ar-NLCs using a QbD approach. Enhanced transdermal permeability, enhanced cytotoxicity on melanoma cells, and sustained release of α-arbutin from NLCs were achieved. These findings indicate that NLCs offer a viable alternative drug delivery system for transdermal applications.

Makale detayları

Development and evaluation of á-arbutin loaded nanostructured lipid carriers for enhanced in-vitro cytotoxic activity in melanoma

Yazarlar:

Mahmut Ozan Toksoy | İlhan Sabancılar

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmacology and Pharmaceutical Sciences (Other)

Dergi:

Journal of Research in Pharmacy Vol.29 Issue 4, pp.1712-1725

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001342460

pISSN:

2630-6344

Box-Behnken design

release kinetics

ex-vivo permeation

cytotoxicity

nanostructured lipid carriers

Sayı

Makale detayları

Development and evaluation of á-arbutin loaded nanostructured lipid carriers for enhanced in-vitro cytotoxic activity in melanoma

Yazarlar: Mahmut Ozan Toksoy | İlhan Sabancılar

Yayıncı: Marmara University

Ana Başlıklar: Pharmacology and Pharmaceutical Sciences (Other)

Dergi: Journal of Research in Pharmacy Vol.29 Issue 4, pp.1712-1725

Belge Tipi: Makale

Yayın Tarihi: 5/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001342460

pISSN: 2630-6344

Box-Behnken design

release kinetics

ex-vivo permeation

cytotoxicity

nanostructured lipid carriers

Sayı

Yazarlar:

Mahmut Ozan Toksoy | İlhan Sabancılar

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmacology and Pharmaceutical Sciences (Other)

Dergi:

Journal of Research in Pharmacy Vol.29 Issue 4, pp.1712-1725

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001342460

pISSN:

2630-6344